Inactive Instrument

Highlights NOVARTIS London S.E.

Equities

0HKE

CH0012005267

End-of-day quote London S.E. Other stock markets
- ^GBX	-

Apr. 26	NOVARTIS AG : Receives a Buy rating from Jefferies	ZD
Apr. 24	BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Novartis Says New Malaria Drug Formulation Safe and Effective for Babies	Apr. 24	MT
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	Apr. 24	RE
Novartis Partnership Says New Malaria Drug for Babies Effective, Safe in Phase 2/3 Trial	Apr. 24	MT
Novartis Faces Lawsuit for Illegal Promotion of Asthma Drug as Preterm Labor Treatment	Apr. 24	MT
Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies	Apr. 24	CI
Novartis Receives FDA Approval for Gastroenteropancreatic Tumor Treatment in Pediatric Patients	Apr. 23	MT
Novartis Wins FDA Approval of Pancreatic Tumor Therapy in Children	Apr. 23	MT
Trending : Novartis Shares Climb on Guidance Lift	Apr. 23	DJ
Novartis Q1 Core Earnings, Net Sales Rise; 2024 Net Sales Outlook Updated	Apr. 23	MT
North American Morning Briefing : Stock Futures Rise, Tesla Earnings in Focus	Apr. 23	DJ
Tranche Update on Novartis AG's Equity Buyback Plan announced on July 18, 2023.	Apr. 23	CI
Novartis AG Revise Earnings Guidance for the Year 2024	Apr. 23	CI
Novartis Lifts 2024 Guidance as First-quarter Earnings Grow on Strong Blockbuster Drug Demand	Apr. 23	MT
Novartis Raises Guidance on Profit, Sales Growth -- Update	Apr. 23	DJ
Techs boost STOXX to one-week high; euro zone data on tap	Apr. 23	RE
Switzerland's Novartis Logs Improved Q1 Net Income, Sales	Apr. 23	MT
Novartis Raises Guidance on Profit, Sales Growth	Apr. 23	DJ
Novartis AG Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 22	CI
US FDA mandates label updates on CAR-T cancer therapies	Apr. 18	RE
Novartis' Multiple Sclerosis Drug Shows Sustained Efficacy for Up to Six Years	Apr. 17	MT